Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease

被引:18
|
作者
Kim, Mi Jin [1 ]
Choe, Yon Ho [2 ]
机构
[1] Inje Univ, Ilsan Paik Hosp, Coll Med, Dept Pediat, Goyang, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Pediat, 50 Irwon-Ro, Seoul 135710, South Korea
关键词
Azathioprine; Inflammatory bowel diseases;
D O I
10.5223/pghn.2013.16.2.65
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active inflammatory bowel disease. Nevertheless, many questions remain concerning the optimal treatment regimens of azathioprine. The dose of azathioprine has to be reduced or the therapy has to be discontinued frequently because of drug-induced toxicity. In this review, we discuss monitoring of thiopurines, adverse events, malignant complications and how to use azathioprine safely and usefully.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 50 条
  • [21] TPMT in the treatment of inflammatory bowel disease with azathioprine
    Qasim, A
    Seery, J
    Buckley, M
    Morain, CO
    GUT, 2003, 52 (05) : 767 - 767
  • [22] Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease
    Kara Bradford
    David Q Shih
    World Journal of Gastroenterology, 2011, 17 (37) : 4166 - 4173
  • [23] Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease
    Bradford, Kara
    Shih, David Q.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (37) : 4166 - 4173
  • [24] The value of mercaptopurine therapy after failing azathioprine in inflammatory bowel disease patients
    Meijer, B.
    Seinen, M.
    Leijte, N.
    Mulder, C.
    van Bodegraven, A.
    de Boer, N.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S383 - S384
  • [25] Neutropenia is not required for clinical remission during azathioprine therapy in inflammatory bowel disease
    Persley, KM
    Present, DH
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2001, 13 (09) : 1053 - 1055
  • [26] Safety and Efficacy of Cyclosporine Therapy in Inflammatory Bowel Disease
    Cullen, Garret
    Keegan, Denise
    O'Donoghue, Diarmuid
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (10): : 2654 - 2655
  • [27] Safety of Biological Therapy in Children With Inflammatory Bowel Disease
    D'Arcangelo, Giulia
    Distante, Manuela
    Raso, Tonia
    Rossetti, Danilo
    Catassi, Giulia
    Aloi, Marina
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2021, 72 (05): : 736 - 741
  • [28] Efficacy and Safety of Azathioprine Therapy in Turkish Patients with Inflammatory Bowel Disease: A Retrospective Long Term Follow Up Study
    Onal, Ibrahim Koral
    Arhan, Mehmet
    Ozin, Yasemin
    Tas, Adnan
    Sezer, Semih
    Tunc, Bilge
    Ulker, Aysel
    TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2011, 31 (03): : 568 - 574
  • [29] A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece
    Christodoulou, D
    Katsanos, K
    Baltayannis, G
    Tzabouras, N
    Tsianos, EV
    HEPATO-GASTROENTEROLOGY, 2003, 50 (52) : 1021 - 1024
  • [30] Usefulness of monitoring the concentration of azathioprine metabolites in the children with inflammatory bowel disease and autoimmune hepatitis
    Bak-Drabik, K.
    Duda-Wronska, J.
    Dabrowska-Piechota, D.
    Adamczyk, P.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S549 - S550